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Background
Why epitope discovery?
The immune system, which is the ‘natural’ 
defense system of most multicellular organ-
isms, can be manipulated in the fight against 
infections, cancer and autoimmune diseases. 
The immune system as a whole reacts against a 
large number of factors, many of which are not 
of protein origin. The innate immune system, 
in particular, reacts quickly against a number of 
compounds supposed to be foreign or very rare 
in a healthy and uninfected individual [1]. The 
adaptive immune system is able to very specifi-
cally react against proteins and peptides specific 
for pathogenic cells and foreign organisms. The 
immune system has for centuries primarily been 
a tool for prophylactic treatments in the form 
of vaccination against pathogens and toxins. 
However, most vaccines, including those that 
are the most successful, have been developed 
empirically without much utilization of spe-
cific immunological knowledge [1]. The insight 
obtained within the last decades, on the other 
hand, has revealed an intriguing potential for 
more rational approaches. This is not only an 
opportunity in the field of vaccine design, but 
also opens up the possibility of highly specific 
therapeutic interventions [2].
Epitopes were originally defined as the part 
of an antigen that defines the binding to an 
immunoglobulin [3]. For antibodies, this is an 
obvious and straightforward definition as the 
immunoglobulin generally binds to the native 
antigen with unambiguously and well-defined 
interactions without any help or interactions 
with other proteins. When considering the 
cellular arm of the adaptive immune sys-
tem, the active immunoglobulin is the T-cell 
receptor (TCR) and the binding partner, the 
antigen, is generally a processed part of a pro-
tein in complex with an MHC protein. Thus, 
in this definition, the epitope will consist of 
part of a processed protein and parts of the 
host-expressed MHC protein. What is usu-
ally of interest, though, is which part of a pro-
tein (peptide) is responsible for an immune 
response. Thus, often this part is referred to as 
the epitope and the native protein from which 
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the epitope originates as the antigen. In the following text, an 
antigen will thus refer to a protein that is able to induce an 
immune response in a given host context. The definition of a 
T-cell epitope will be a subpeptide from the antigen, which is 
able to complex with a host MHC and, in this context, can be 
recognized by antigen-specific TCRs.
Epitope discovery is obviously of major interest in traditional 
protective vaccine research. Here, the identification of specific 
epitopes can lead to the identification of important antigens and 
help define the most important parts of selected antigens [4]. 
In traditional vaccine development, such information is impor-
tant in order to ensure that selected production strains and sub-
types carry the relevant versions of the most important antigens. 
Recently, the knowledge of specific antigens and epitopes has 
been used to guide the design of minimal vaccines consisting of 
only the relevant antigens [5], which will very likely soon lead to 
vaccines consisting of minimal artificial polypeptides designed 
to contain several strong epitopes relevant for the specific dis-
ease [6]. In addition to protective vaccinology, the potential of 
using immune-related tools to fight established diseases such 
as cancer and chronic infections attracts increasing interest. 
Immunotherapy is the general term of two, conceptually very 
different, approaches. First, most mature, and increasingly used 
in the clinic, is the use of monoclonal antibodies against a specific 
disease target [7]. The second approach is to manipulate a patient’s 
immune system to focus on specific disease-related targets that 
are otherwise being ignored by the host immune system. Here, 
carefully selected epitopes might be used to induce a more potent 
and efficient immune response.
The knowledge of which strong epitopes a protein contains has 
further importance when considering the use of proteins and pep-
tides as therapeutic drugs. Here, epitope identification can be used 
for deselection or de-immunization purposes, where therapeutic 
proteins, including monoclonal antibodies, that might otherwise 
have unwanted immunogenic effects can be deselected early in the 
preclinical phase or the proteins may be de-immunized by removal 
of identified epitopes [8]. Finally, epitope identification is of gen-
eral interest in basic immunology. The studies of how and when 
specific epitopes will or will not lead to immunogenic responses 
and which signaling pathways coincide with specific epitopes is an 
important part of immunology research that can help in the general 
 understanding of the behavior and evolution of the immune system.
From antigen to epitope: processing & presentation of 
T-cell epitopes
For the sake of the later descriptions of different prediction 
approaches, the key events in cellular immune responses are 
briefly summarized here with an emphasis on the events that 
have been successfully characterized by prediction methods, and 
other known important events that are presently not predictable 
by mathematical models or computational algorithms.
T-cell epitopes in complex with MHC proteins are recognized 
by TCRs on the surface of T cells with different functionality, 
T-helper (Th) cells and cytotoxic T lymphocytes (CTL). Besides 
having different coreceptors, CD4 and CD8, respectively, the 
MHC molecules presenting Th epitopes or CTL epitopes have 
some important differences that seem to be universal for jawed 
vertebrates, with one recently discovered exception in cod, as 
this fish seems to be lacking the genes that are specific for Th 
responses [9]. Furthermore, only a limited panel of animals have 
been investigated in depth with respect to their immune systems, 
thus this section will consider primarily the knowledge obtained 
by studying the human immune system.
The CTL response is induced when a TCR on a CD8+ T cell is 
able to bind to an MHC class I–peptide complex presented by a 
nucleated cell. Peptides bind to the MHC class I in a defined bind-
ing groove that is closed at the end so that binding peptides are 
limited in length, where most MHC class I molecules prefer bind-
ing to peptides of nine amino acids in length (Figure 1A). The MHC 
class I proteins are able to exchange bound peptides with free pep-
tides in solution if available, but generally the peptides presented 
on the surface of a cell originate from longer poly peptides and 
proteins produced within the cell. The pathway of MHC class I 
peptide presentation is described in detail in a number of recent 
reviews [10–12], and is an extension of the general protein turnover 
machinery present in all eukaryotic cells. The proteasome com-
plex digests proteins labeled with the regulatory protein ubiquitin, 
producing short peptides. Thus, under normal circumstances, 
this process is performed by the constitutive proteasome that has 
strong stochastic elements in cleavage preferences [13,14]. However, 
careful mapping of cleavage sites has led to a general description of 
the cleavage specificity [15]. In immune-alert cells, certain subunits 
in the proteasome complex that are responsible for the actual 
cleavage are replaced, and the cleavage becomes more specific, but 
still with stochastic elements. This variant of the proteasome is 
generally referred to as the immunoproteasome, and the change in 
specificity moves the length distribution of the peptide products 
towards longer peptides. Some of the generated peptides will be 
able to bind to the transporter associated with antigen processing 
(TAP) and transported into the endoplasmic reticulum (ER). 
Upon entrance to the ER, the peptide will encounter semifolded 
MHC class I molecules anchored at the inner side of the ER 
membrane. Suitable peptides will induce further folding of the 
MHC as the peptide fully enters the ER, further enabled by the 
protein tapasin that has a chaperone-like function [16,17]. Fully 
folded MHC–peptide complexes will be transported to the cell 
surface where they will be available for binding by a suitable TCR.
Th responses will be induced if a TCR on a CD4+ T cell binds 
to an MHC class II–peptide complex, which is generally expressed 
in professional APCs [18]. The MHC class II binding groove is 
open at both ends allowing binding of peptides of any length 
(Figure 1B). Also, the MHC class II-presented peptides have usu-
ally been subject to substantial processing before presentation 
at the cell surface, and this process has been reviewed in detail 
elsewhere [19–22]. Generally, the presented peptides originate 
from from native or partly degraded proteins or protein com-
plexes from the extracellular space. The proteins have entered 
the APC by phagocytosis and continued into the endosomic 
pathway, where the protein will be denatured and processed by 
proteases such as the cathepsins, although the specificity of these 
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are not fully understood [23,24]. Membrane-
anchored MHC class II molecules are pres-
ent in the endosomes, fully folded with the 
invariant chain (Ii) in the binding groove. 
The Ii undergoes proteolysis, and the 
MHC class II binding groove will finally 
be occupied by only a part of the Ii, the 
MHC class II-associated invariant chain 
peptide (CLIP). CLIP is then exchanged 
with free peptides resulting from proteoly-
sis of the phagocytosed antigens facilitated 
by the action of HLA-DM. Local struc-
tural properties of the source antigen have 
been shown to influence antigen processing 
and/or the accessibility of peptides to the 
MHC class II molecule, imposing a bias 
so that fragments that are exposed in the 
native fold of antigens are more likely to 
be presented compared with peptides from 
the antigen protein core [25]. Loaded MHC 
class II is next transported to the cell sur-
face, available for potential recognition by 
CD4+ T cells carrying an appropriate TCR.
The above-described pathways are sim-
plified and a number of exceptions have 
been described, such as alternative routes 
for MHC class I-presented peptides to be processed and enter 
the ER [26–28]. Furthermore, in recent years it has become more 
evident that the pathways for MHC class I and MHC class II 
peptide presentation are not always separated and that peptides 
from autophagocytosed extracellular proteins can end up being 
presented by MHC class I proteins. This phenomenon is generally 
described as cross-presentation [29,30].
MHC genes & proteins
MHC class I and II proteins share extensive overall structural 
similarities (Figure 1) but are constructed differently. MHC class I 
proteins consist of a membrane-anchored a chain and a smaller 
b-2-microglobulin chain. The a chain has three structural 
domains and is linked noncovalently to the b-2-microglobulin 
chain via interactions of the three domains. The binding groove 
is made up by the a 1 and a 2 domains and is closed at the ends, 
which restricts the length of the peptides that will be able to bind 
to the MHC. Generally, peptides 8–13 amino acids in length are 
considered able to bind to the MHC, with a preference of nona-
mer peptides. However, even longer epitopes have been reported 
[31]. The structure of the MHC molecule has revealed a number 
of binding pockets important for peptide binding specificity, and 
for MHC class I two major pockets exist, placed in each end of 
the binding groove in such a way that generally peptide amino 
acid number 2 and the C-terminal amino acid will bind in these 
pockets [32,33]. In humans the a chains for the classical MHC 
class I proteins are encoded by genes at the HLA-A, -B and -C 
loci. These genes are highly polymorphic, and thousands of HLA-
A, -B and -C alleles have at present been reported [34]. Most of 
the polymorphic sites are placed in the binding groove and will 
influence which peptides will be able to bind the particular MHC 
(Figure 1A).
MHC class II proteins consist of two membrane-anchored poly-
peptide chains, an a and a b chain. The binding groove is made 
up of domains from both the a and the b chain, the a-1 and the 
b-1 domains (Figure 1B). The binding groove is open ended, which 
enables binding of longer peptides, and generally peptides 12–20 
amino acids in length are observed [35]. However, the length of 
the binding groove resembles that of MHC class I and only nine 
consecutive amino acid residues from the binding peptide are in 
contact with residues in the binding groove. The MHC class II 
binding groove has special pockets that will fit defined amino 
acids of the binding peptide, and have a major influence on the 
binding energy [36]. In humans MHC class II chains are encoded 
by genes in the HLA-DR, -DQ and -DP loci. HLA-DRa chains 
are expressed from a single locus (HLA-DRA) and no functional 
variations have been reported. HLA-DRb chains (HLA-DRB) 
can be expressed from several loci (HLA-DRB-1, -3, -4 and -5) 
where most individuals will express the gene present at the HLA-
DRB1 locus. Almost 1000 HLA-DRB1 alleles have presently been 
identified, expressing more than 700 variant proteins, whereas 
just 46, eight and 16 protein variants have been identified for 
HLA-DRB-3, -4 and -5, respectively [34]. For HLA-DQ and -DP 
only one a (HLA-DQA1 and HLA-DPA1, respectively) and one 
b (HLA-DQB1 and HLA-DPB1, respectively) locus is active at 
each chromosome. However, for HLA-DP and -DQ, both the a 
and b chains are polymorphic with one to two dozen a variants 
and a little more than 100 b variants each. Furthermore, a and 
Figure 1. Structural surface representations of MHC class I (A) and MHC class II 
(B) molecules in complex with peptide shown in stick representation. (A) The 
peptide is green and the residues in the a chain considered important for peptide 
binding [73] is colored dust green. The rest of the a chain is dark blue and b-2-
microglobulin is light blue. (B) The binding core of the peptide is dark green, and the 
rest of the peptide is bright green. The residues in the b chain considered important for 
peptide binding [83] are colored dust green. The rest of the b chain is colored dark blue, 
and the a chain is light blue. The figure has been created using PyMol with the PDB 
available templates of an HLA-A*11:01-peptide complex structure, 2HN7 [105] (A) and an 
HLA-DR1-peptide structure, 1AQD [106] (B).
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b chains can combine with the corresponding partner expressed 
from either the cis or the trans chromosome, resulting in up to 
four different class II proteins per locus. As for MHC class I 
the polymorphic sites are predominantly present in the bind-
ing groove and will thus be responsible for diversities in peptide 
binding specificities. Thus, in principle each allelic version of 
an MHC molecule will bind a specific set of peptides. As epit-
opes are a true subset of what are able to bind the MHCs of a 
given individual, the high degree of polymorphism imposes a 
big challenge on epitope discovery. Fortunately, not all alleles are 
equally (in)frequent. Almost half of the European population will 
have the class I HLA-A*02:01 allele according to the two major 
web-accessible allele frequency databases, alllelefrequencies.net 
[37] and dbMHC [38]. The HLA-A*02:01 allele is also the most 
investigated HLA allele so far, with 1287 reported CTL epitopes 
available from the major epitope deposit, the ImmuneEpitope 
database (IEDB) [39]. For other frequent european alleles such 
as HLA-A*01:01 (~30% ) and HLA-B*07:02 (~25%), the num-
bers are 68 and 136, respectively. Despite this bias, a number of 
different alleles have actually been examined and it appears that 
some alleles have similarities at sequence positions coinciding 
with the major binding pockets, and that these alleles also show 
similarities in peptide binding preferences. This observation led 
to the suggestion that the alleles could actually be clustered into 
a dozen functional clusters, named supertypes [32]. 
Experimental approaches for T-cell epitope discovery, 
detection & validation
A number of assays have been developed to detect and verify 
T-cell epitopes, and these methods have recently been described 
in more detail [40–42]. Each of these methods have various benefits 
and pitfalls and should be carefully considered with respect to the 
purpose of the experiment.
Stimulation in vitro or in vivo
In classical antigen discovery, T cells were stimulated to prolifer-
ate with antigens and cytokines. Proliferated T cells were cloned 
and used to screen COS cells expressing both the relevant HLA 
and one of several potential antigens in a cDNA library setup. 
This approach would reveal which antigen was the parent of the 
stimulating epitope. Other, very tedious, steps could be included 
in order to reveal the actual epitope. T-cell cultures could also 
be stimulated by bare peptides; however, this procedure imposes 
the question of whether the T cells will react to cells that have 
processed the parent antigen [40]. Lack of recognition could be 
due to the fact that the native antigen might not be processed 
correctly, and such peptides are referred to as cryptic. Today, the 
concept of being cryptic is often interchanged with being sub-
dominant. Epitope dominance is the concept that only certain 
peptides from a given antigen/pathogen will be epitopes in a given 
individual (dominant epitopes), but in cases where the dominant 
epitopes are absent from the antigen, other peptides will now 
be able to induce an immune response [43]. This phenomenon 
has not been pinpointed as being caused by any single or few 
events but is most probably a result of competition on several or 
all steps in the immunogenic pathway [44]. These steps includes 
expression level, stability of the antigen, all the different steps 
in the given presentation pathway and finally the TCR affinity 
towards the MHC–peptide complex [43,45]. Even if subdominant 
epitopes are not immunogenic determinants in the native antigen 
or pathogen context, it is often possible to detect a strong recall 
response against the native antigen using T-cells stimulated with 
the subdominant epitope either in vitro or in vivo.
Instead of in vitro stimulation of T cells, it has been shown to be 
possible to use peripheral blood mononuclear cells (PBMCs) con-
sisting of T cells, B cells, NK cells, basophils and DCs. If taken 
from an individual (animal or human) that has been exposed to 
a given antigen, either by vaccination or natural infection, it is 
possible to detect a T-cell response when the PBMC is stimulated 
with the peptides containing the right epitopes. This response can 
be detected by the amount of released cytokines (e.g., IFN-g) in 
ELISA, enzyme-linked immunosorbent spot assays or by intracel-
lular staining. All three methods demand that antibody staining 
reagents have been developed for detection of the given cytokine. 
This has been achieved for mice and men, but for many animals 
the reagents are not readily available, if at all. The first two meth-
ods can easily be performed in multiwell plates, but have the 
disadvantage that additional extensions have to be introduced in 
order to be able to distinguish between responses from different 
cell types, such as CD4+ and CD8+ T cells. By use of intracel-
lular staining in combination with flow cytometry it is possible to 
simultaneously detect the activation state and cell type of a given 
cell. This can in principle be done in a high-throughput (HTP) 
system; however, the preparation of the collected data still needs a 
large degree of human intervention. Using PBMCs from infected 
(previous or current) or vaccinated individuals will lead to the dis-
covery of basically only dominant epitopes. In order to optimally 
discover subdominant epitopes by purely experimental methods, 
several rounds of immunizations have to be performed with new 
antigens in which the dominant epitopes are no longer present.
However, subdominant epitopes might be important in vaccine 
development for several reasons. Regions containing subdominant 
epitopes are less influenced by selective pressure by the human 
immune system and therefore cover more of the pathogen strain 
variation, or might for other reasons turn out to be more effective 
for use in vaccines [44,46–48].
Peptide pools
When mapping immune responses using peptides, the bind-
ing nature of the MHC has to be considered. As described ear-
lier, preferentially nonamer peptides will bind to MHC class I 
molecules, but it is possible to use longer peptides in the recall 
assays [41]. Often peptides 15–20 amino acids in length will be 
used when a full antigen, or even a full viral proteome, is to be 
scanned. As the binding core of both MHC class I and class II 
binding peptide is nine consecutive amino acids, peptides will 
have to overlap with at least eight amino acids in order for all 
nonamer binding cores to be present in at least one peptide. 
To lower the considerable experimental effort, the peptides are 
pooled in samples with up to 64 peptides per pool and prepared 
www.expert-reviews.com 47
PerspectivePredictions versus high-throughput experiments in T-cell epitope discovery
in a matrix system. The longer peptides often give a cytotoxic 
immune response even if the actual reacting peptide is usually 
8–11 amino acids in length. This is most likely because the pep-
tides will be partly digested by proteases present in the monocyte 
suspension, even though the origin of such protease/peptidase 
activity has at present not been fully identified [49]. The use of 
longer peptides also has the benefit that the same peptides may 
be used both in CTL and Th epitope mapping [41,50]. In order to 
identify the exact epitope, often referred to as the ‘minimal’ epit-
ope, new shorter versions of the reactive peptide must be designed 
and used in additional assays, preferably without the interference 
of the proteolytic effects. This can, however, be a challenge, as 
the living cells in the assays might potentially secrete proteases, 
which can lead to the observation that peptides with weak bind-
ing to the relevant MHC molecules give strong CTL responses 
whereas peptides with more optimal binding do not. To unam-
biguously verify the minimal epitope, MHC–peptide binding 
should be tested by biochemical assays, as described in the next 
section. If the peptide can in fact bind to the restricting MHC 
protein, a strong method of verification of the minimal epitope 
is to create MHC–peptide multimers in order to detect T cells 
with a compatible TCR. The concept has recently been reviewed 
[51]. The MHC-multimer is prepared with synthetic peptides of 
interest that are able to bind the MHC and are subsequently used 
as markers in flow cytometric assays. MHC multimers are ideal 
to verify whether the T cells of interest recognize the particular 
MHC–peptide complex, and to assess the amount of specific 
T cells. MHC-multimers are most commonly used in the origi-
nal form, as tetramers [52]; however, several variants have been 
made with higher number MHC–peptide complexes per entity 
(e.g., as pentamers or dextramers [53,54], or improved functional-
ity in the form of streptamers [55]). In the end, however, it can be 
hard to estimate whether a given epitope is actually presented 
on infected or malign cells. For this purpose, it should be pos-
sible to clone TCRs generated by artificial stimulation and tested 
for specificities using MHC multimers. The TCRs can then be 
used as markers in flow cytometric assays in order to detect cells 
presenting the peptide.
MHC class I–peptide binding assays
The MHC–peptide binding is the most restrictive step in the 
peptide presentation pathway [43]. Thus, the affinity of peptides 
to a given MHC is a strong indication of whether the peptide 
is a potential epitope or not. For this reason, a number of bio-
chemical assays have been developed in order to determine the 
MHC–peptide affinity. A classic method is a competition assay 
where a usually radioactively labeled reference peptide is bound 
to the MHC. The labeled peptide is then competed out with 
increasing concentrations of the peptide in order to estimate the 
IC
50
 value, which, depending on the reference peptide affinity, is 
considered to be close to the constant of dissociation (Kd). Several 
HTP affinity assays have been developed, spanning from spin 
column-based gel filtration, over ELISA, to highly automated 
proximity assays [56]. The automatization of the measurement of 
MHC–peptide binding has been an important factor leading to 
the fact that now more than 100,000 different MHC–peptide 
affinities have been measured and are available from the IEDB.
Predictions of T-cell epitopes
The above-described experimental methods are all relatively 
resource intensive even using the newest HTP methods, espe-
cially if several HLA types must be considered. The cost of syn-
thetic peptides alone are still in the order of US$10–100 per 
peptide dependent on purity, and with a standard protein length 
of 200–300 amino acid residues, the price of a complete protein 
scan is still significant and a full scan of all potential antigens 
from more complex organisms such as bacteria and large viruses 
is not presently feasible, even for a single HLA type.
Prediction of peptide binding to MHC class I
Because of the amount of resources demanded for complete epit-
ope scans, in silico predictions of T-cell epitopes is of major interest 
in epitope discovery. Here, it is worth mentioning that not only is 
it a necessity for a peptide to be able to bind an MHC to become 
an epitope, it is also the most restrictive step in the pathway from 
native protein to an immune response. On average, only one in 
200 of the possible peptides that can be generated from a native 
protein will be able to bind a given MHC class I protein [43]. 
Even though these numbers are more uncertain regarding MHC 
class II, in both cases, specific positions in the binding peptide 
are responsible for the majority of the binding affinity, making 
MHC–peptide binding an interesting subject for development of 
prediction methods [14,35,57,58]. Any prediction method is depen-
dent on data, at least for evaluation, although some approaches, 
such as structure-based methods using knowledge of docking and 
molecular interactions [59–61], have been developed using only very 
few measurements of MHC–peptide binding. The most accu-
rate prediction methods, however, are data-driven and depend 
on large amounts of binding data in order to be able to develop 
various prediction models. For these methods, it has been a clear 
observation that the more data, the more accurate the predictions. 
Pre-experimental use of, and filtering by, successful prediction 
methods naturally greatly improve the success rate in experimen-
tal assays as more of the tested peptides will turn out to be binders. 
However, as the information that a peptide is able to bind a given 
MHC is much more valuable in prediction development than 
a nonbinder, this increase in binder identification has further 
improved the prediction methods. Thus, very beneficial scientific 
collaborations generating iterative assay–prediction–assay loops 
have been practiced between experimentalists, assay developers 
and bioinformatics prediction developers, which have further sped 
up the process of developing accurate prediction methods [62]. As 
the price of synthetic peptides is not insignificant, only peptides 
predicted to bind to an MHC will be synthesized and tested. This 
iterative process has an inherent risk of developing predictors that 
are only able to predict a limited part of the potential MHC bind-
ers. In the next iteration of training the newly measured data will 
be used and only in the cases were the predictions are false will 
the system be given new information in the next iteration. False 
predictions will then always be a predicted binder that turned out 
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to be a nonbinder. The complementary situation will not occur 
as predicted nonbinders will never be tested. In order to at least 
partly circumvent this problem, methods have been developed to 
assess the confidence of the predictions. These measures have then 
been used to select peptides believed to be in the periphery of the 
known space. The affinity of such peptides is then measured and 
fed back into the loop [62]. This method will not guarantee that 
submotifs very different from those already estimated will not be 
missed. Thus, full peptide scanning of various antigens of interest 
is still of major importance in order to get unbiased inputs into 
the development cycle. Full antigen scans will also be important 
in order to get an unbiased validation of the prediction methods. 
As described previously in the text, the HLA molecules are 
highly polymorphic and the issue of identifying which peptides 
bind any given HLA is important in order to understand how 
different individuals and populations react to certain stimuli. 
Thus, in principle, the whole peptide identification, binding 
measurement and prediction cycle should start from scratch for 
each new MHC allele, of which thousands of different alleles are 
known at present [34]. Furthermore, MHC–peptide binding assays 
have been broadened to include most of the more common HLA 
types in human as well as MHCs from the most used strains of 
inbred mice. As described, a HLA supertype consists of a number 
of HLA-encoded proteins binding basically the same peptides. 
However, how to cluster the HLAs and how to score the overlap 
in peptide binding space is not a trivial task, indicated by the 
fact that a number of different methods have been used for the 
purpose [32,63–66]. Naturally, the smaller the sequence distance 
between two proteins, the bigger the chance that they will bind 
the same peptides, but many exceptions have been observed, and 
even for two HLAs that have a high degree of homology, a signifi-
cant number of the peptides that will bind to one protein might 
not bind to the other. This can be exemplified with the two very 
similar HLAs, HLA-A*30:01 and HLA-A*30:02. According to 
the definitions of Sidney et al. these could both belong to the A1 
supertype [32]. However, HLA-A*30:01 are also assigned to the A3 
supertype, which is confirmed by the work of Lamberth et al. [67]. 
Using the web accessible tool, MHC Motif Viewer [68], it is also 
apparent that the two HLAs have considerable differences in their 
peptide binding motif (Figure 2). These distinct binding patterns 
have been verified using peptides parented by a Mycobacterium 
tuberculosis antigen [69].
One of the most complicated parts in MHC–peptide bind-
ing assays is to get folded or refoldable MHC proteins expressed 
from a large number of different alleles, and one of the more 
expensive parts is the synthesis of peptides. However, it has been 
a relatively inexpensive and uncomplicated task to test peptides 
already synthesized, for their ability to bind to several of the MHC 
proteins available. This synergy has enhanced the quantity of 
available affinity data for each HLA allele significantly as peptides 
synthesized with the assumption of being able to bind a specific 
HLA allele have been measured by testing them against a large 
number of different MHC proteins. These kinds of data have been 
of great value in developing prediction systems because peptides 
not necessarily predicted to bind to a given MHC nevertheless 
sometimes turn out to be able do so. The data are important for 
the iteration loops because they limit the risk of only being able 
to predict a part of the possible motif space. Furthermore, having 
peptide binding data for a large diversity of different peptides to a 
high diversity of MHCs has made it possible to create prediction 
systems that are able to predict not only whether new peptides 
will bind to previously characterized MHCs, but also predict 
the affinity of new peptides to new MHCs for which no peptide 
affinity data are yet available [70,71]. Where the single allele predic-
tors are trained to deduce a binding motif from a large number 
of peptides known to bind to a given MHC, the most successful 
pan-allele predictors have been trained to predict the affinity of 
a given MHC–peptide combination. The amino acid sequence 
information from the full binding peptide is combined with 
the amino acid information regarding the residues in the MHC 
sequence known to influence binding so as to be used as input for 
the training (Figure 1) [58,72,73]. With these systems, accurate predic-
tions can now be made for basically all HLA class I proteins and 
for several animal class I MHCs as well, including those of pigs, 
mice and nonhuman primates. Predictions of peptide binding to 
most HLA class I and chimpanzee MHC class I variants are at 
present very accurate. The errors between measured and predicted 
affinities are generally very close to the difference in the measured 
affinity using two slightly different binding assays [57,70,74]. The 
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Figure 2. The Kullback–Leibler binding peptide sequence 
logo for the HLA-A*30:01 (A) and HLA-A*30:02 (B) alleles 
is generated using the MHC Motif Viewer website. The 
Kullback–Leibler information content is plotted along the 
nonamer. Amino acids with positive influence on binding are 
plotted on the positive y-axis, and amino acids with a negative 
influence on binding are plotted on the negative y-axis. The 
height of each amino acid is determined by their relative 
contribution to the binding specificity.
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pan-specific method often outcompetes the single allele trained 
methods, and a combination of the two is generally even better. 
For this reason, a new web server has been developed that will 
automatically decide the optimal combination of predictions to 
use [75]. Concerns have been raised that available MHC–peptide 
binding prediction methods can only be used to predict binding 
of peptides eight, nine and maybe ten amino acid residues in 
length [31,76]. However, methods have been developed that are 
able to predict longer peptides [77] and these methods have been 
included in a number of different prediction schemes [74,78,79]. 
The length approximation method has currently been bench-
marked to perform well on peptides ten and 11 amino acids in 
length, which are the lengths that have enough available bind-
ing data to carry out statistically robust validations. However, 
the method can, in principle, also be used for longer epitopes. 
Both proteasomal cleavage and TAP binding can be predicted, 
and integrated prediction systems have been developed (for more 
information, see [15,58,80]). However, even though the improve-
ment of prediction accuracy regarding verified MHC ligands has 
been statistically significant, the impact seems to be marginal 
compared with MHC binding predictions alone [79]. This fact is 
probably linked to the  coevolutionary effect on connected steps 
in the pathway [81,82].
Prediction of Th epitopes
For MHC class II binding, it is inherently harder to go from pep-
tide binding data to a defined motif of the binding core as this is a 
continuous stretch of nine amino acid residues placed somewhere 
in a larger peptide usually in the range of 12–20 residues in length 
(Figure 1B). Furthermore, MHC class II proteins consists of two 
chains and both chains participates in peptide binding. Also, in 
the case of HLA-DQ and -DP, both chains contains polymorphic 
residues. Whereas the issue regarding defining the binding core 
is mainly a theoretical problem that can in principle be deduced 
from large sets of binding data, MHC class II is also an experi-
mental challenge as it has turned out to be much harder to do 
in vitro folding of recombinantly expressed MHC class II. Thus, 
at present, we do not have the same degree of HTP biochemical 
assays for MHC class II proteins as for MHC class I, and far fewer 
different MHC class II proteins have been investigated in relation 
to peptide binding. As mentioned before, placing the binding core 
correctly is a challenge; thus, not only do we have far less binding 
data available for MHC class II protein–peptide binding, but we 
do not get the same improvement in pre-
diction accuracy per data point because of 
this higher degree of uncertainty. Since the 
first prediction methods on MHC class II 
binding, the fields have developed slowly 
compared with MHC class I. However, at 
present, validated accurate predictions of 
peptide binding to several HLA-DR alleles, 
and some HLA-DQ and -DP alleles, are 
available [83].
Moreover, for MHC class II peptide 
binding, pan-MHC prediction methods 
have been developed, enabling predictions for basically any 
mammalian MHC class II protein. However, the predictions of 
nonhuman mammal MHCs have only been validated for a very 
limited number of alleles owing to lack of data [84]. Even though 
it is possible to create class II multimers, it has turned out to be 
technically more complicated to produce refoldable MHC class II 
recombinantly [85,86].
Accuracy of in silico methods
The HLA class I binding predictions for some alleles have for 
some time been very accurate, as exemplified with a test on pre-
dicted HLA binding peptides from the SARS proteome. Here, 
86–93% of the tested peptides turned out to be binders for alleles 
for which a mature prediction system aleady existed [87]. Some of 
the methods have recently been compared in an open competition 
[88], where it was clearly shown that basically all newer prediction 
methods are better than the two pioneer methods BIMAS [89] and 
SYFPEITHI [90], which, despite this fact, are still widely used in 
epitope discovery. Hopefully, these kinds of competitions will 
continue and develop to concern not only MHC class I binding 
but also class II binding and actual epitope discovery success rates. 
Based on accuracy, speed and consistent availability, we generally 
recommend the tools listed in TABle 1.
In terms of the accuracy of epitope prediction, the validation is 
more complicated, as what is immunogenic in one might not be in 
another, for various reasons. Thus, the more individuals that are 
tested, the higher the chance of getting a positive response, pro-
vided the peptide is immunogenic at all. In an experiment where 
highly conserved influenza peptides were tested in individuals 
supposed to have had an infection within the last 3–7 years we 
found that 10% of the binding peptides could elicit a CTL recall 
response [91]. However, the time span from the immunogenic 
event to detection has a major influence on the success rate, as 
exemplified by the attempt to detect CTL responses more than 
30 years post-vaccinia virus vaccination [92]. Here, only 6% of the 
predicted binders were able to induce a recall response. The state 
of an infection is also important, as in acute infections the hit rate 
has been shown to be much higher. That prediction methods are 
strong prefiltering tools has been shown in an attempt to discover 
all possible epitopes in vaccinia in mice after vaccination [93]. In 
this scenario, only 1% of peptides were selected based on MHC 
class I binding predictions, and 95% of the immunogenicity could 
be explained by 50 peptides within this selection.
Table 1. Recommended MHC binding prediction tools†. 
Name Prediction Immune Epitope 
Database analysis tool‡
CBS prediction 
servers§
NetMHCpan MHC class I binding NetMHCpan NetMHCpan
NetMHCCons MHC class I binding NetMHCCons
SMM MHC class I binding smm
NetMHCIIpan MHC class II binding NetMHCIIpan NetMHCIIpan
†Some are available from several online sources as shown below.
‡Data from [107]. 
§Data from [108].
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Prediction of peptide binding to animal MHCs
Whereas we have extensive knowledge of the HLAs and MHCs 
of the most animal models used in research (i.e., mice and chim-
panzees), we lack fundamental knowledge of many other animal 
species. Some genetic variations are known for important animals 
in food production, but the variation and differences in these 
genes between mammals are extensive. Rhesus monkeys, for 
example, have several MHC class I loci that individually are less 
variable than HLAs, but turn out not to all be expressed in a given 
individual. Also, MHC class II genes show species differences, 
as in cattle and goat it seems that they are analogs to the human 
HLA-DRB3 genes that display the most extensive polymorphism. 
Furthermore, MHC binding assays and epitope discovery tools 
are still only developed for very few species, including pig and 
cattle. However, despite the limited possibility of thorough bench-
marking, it has been shown that MHC class II predictions can to 
some extent be applied to cattle [94], and pan predictors have been 
able to predict peptide binding to pig MHC class I [95].
Expert commentary
In this article we have described a number of methods used for 
T-cell epitope discovery. At present, HTP ex vivo assays do not 
have the sensitivity of the more elaborate assay types, and it is 
not feasible to make a full peptide proteome scan for an exten-
sive number of HLA alleles, even for relatively simple pathogens. 
Furthermore, by use of pure assay-based methods it is a challenge 
to identify the subdominant epitopes that might be crucial in 
prevention or treatment of certain diseases. On the other hand, 
in silico models can help identify potential subdominant epit-
opes. Using in silico methods in the primary selection of peptides 
can successfully be combined with other selection criteria, such 
as conservation state of the potential epitope. In the previously 
mentioned example of discovery of CTL epitopes induced by 
influenza A H1N1 infections, this led to the discovery of 13 epi-
topes, of which 11 were fully conserved in the H5N1 avian strain 
that has been responsible for several fatal infections in humans 
[91] and all were conserved in the recent H1N1 influenza pan-
demic. The selection schemes have been further developed to 
include strain variability, and also to benefit from predictions of 
all alleles of a given population and include the allele frequencies 
obtained from databases. In this way, a pool of peptides has been 
predicted that should optimally cover all HIV strains and most 
of the human population. In such experiments, we see that up to 
70% of the selected peptides will elicit a response in at least one 
individual [96,97]. This approach will take over from the previ-
ously described supertype approach as it will be more sensitive 
and accurate, and is better suited for taking different populations 
into consideration.
Epitope prediction systems will probably never be able to detect 
all the possible epitopes in a given setup. However, some experi-
mentalists seem to neglect that experimental assays are also only 
accurate to a certain sensitivity and specificity, which is in fact 
the general condition for all natural sciences. It has been argued 
that prediction systems are in general not sensitive enough and 
that resources are better spent on thorough HTP scans [76,98]. 
The fact that there are no valid data that go against the generally 
reported high accuracy of MHC–peptide binding predictions 
has been argued elsewhere [33]. Even though new methods have 
been developed that are able to predict binding of longer peptides, 
the Burrows paper [31] is still put forward as an argument against 
prediction methods [76]. It is our strong belief that it is possible 
to successfully predict a large majority, if not all of the 25 longer 
epitopes mentioned in the paper by Burrows et al. Furthermore, 
Wu et al. argue that some newly identified epitopes cannot be 
predicted based on the claim that they do not contain the correct 
motif [76]. It is, however, possible to test for peptides 8–11 amino 
acids in length using existing tools such as HLArestrictor [82] 
and NetMHCcons [101]. We strongly belief that the use of these 
tools will show that a majority of the epitopes claimed not to be 
predictable will turn out to be so.
In the end, it is our opinion that it is not a choice between 
two scenarios where, in one scenario, prediction methods lead to 
the end of experimentally based assay procedures, or, in another 
scenario, of experimental puritanism in which every step in an epi-
tope discovery effort has to be based on positive results in experi-
mentally based assays alone, thereby excluding the involvement of 
theoretical-based selection. It is our strong belief that a concerted 
effort in a nonhostile arms race of the development of assay pro-
cedures and computational modeling will lead to mutual benefits 
where each side will strongly benefit on the progress of the other.
Five-year view
As described in the previous sections, the field of T-cell epitope 
prediction is expected to develop significantly within the next 
few years. The amount of data for MHC class II–peptide binding 
will most likely increase significantly, leading to better prediction 
systems for MHC binding. Also very likely is that we will see 
accurate predictions not only for all HLA-DR alleles, but also 
for HLA-DQ and -DP alleles, and probably for MHC class II 
proteins from several other mammals as well. A new possibil-
ity for HTP assays has been developed in recent years that will 
potentially have a great impact on the amount of available MHC 
class II–peptide affinity data. Peptides spotted or synthesized in 
microarrays can be used to measure a very high number of differ-
ent peptides in one go. The micro-array peptide chip technology 
is maturing now and will be very suitable for such multipeptide 
assays in the future, especially for MHC class II because of the 
open ends of the peptide binding groove enabling the MHC to 
bind even though the peptide is immobilized in one end.
The newly discovered involvement of MHC class I pathway 
elements in presentation of MHC class II restricted peptides will 
certainly be investigated and might improve significantly on Th 
epitope predictions [12]. The MHC class I–peptide binding pre-
diction systems will be highly accurate for most mammals, and 
it is very likely that usable prediction systems will be available for 
several bird alleles as well. The development of direct epitope pre-
diction systems will move slower because of the resources needed 
in generating the data and the complexity involved in discriminat-
ing immunogenic MHC binding from nonimmunogenic MHC 
binders. The effect of MHC–peptide stability measurements and 
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predictions of this will be an important integration in prediction 
of T-cell epitopes. New and improved knowledge of TCRs, posi-
tive and negative selection in the development of TCR specificity, 
and the interactions between the TCR and the MHC–peptide 
complex will also be obtained as a result of recent discoveries, 
combined with the new and emerging, fast and cheap sequencing 
methods. Such knowledge will undoubtedly have a significant 
impact on the modeling of usable true Th and CTL immune 
response models already at the end of the coming 5-year period. 
As data increase and prediction methods develop, a much greater 
understanding will emerge on what defines a dominant T-cell 
epitope. We believe that we will observe a preliminary HLA hier-
archy that will explain some of the dominance effects that we see. 
The understanding of dominance will probably further increase 
when we gain knowledge of how specific TCR germline genes 
influence the preferences of the TCR for specific MHC–peptide 
complexes. Likewise, evidence is emerging that suggests that the 
integration of signals from other immune system receptors, such 
as KIR, has a strong impact on our T-cell immunity and epitope 
dominance [99]. Recently, a new accurate MHC–peptide stability 
HTP assay has been described [100], and it will be interesting to 
follow in the coming years whether stability will be an even better 
indicator of peptide immunity than affinity.
The first field where selected epitopes will have a clinical impact 
is probably in cancer treatments based on specific selected T-cell 
epitopes. Several trials are already initiated for various cancer types 
(for more information see [102–104]). These epitopes are often iden-
tified using one or more in silico methods combined with more 
traditional assay-driven discovery methods. Within traditional 
vaccine development, it is our impression that several developers, 
especially smaller startup companies, are using prediction methods 
as a major step in epitope discovery to design vaccines with spe-
cially selected epitopes in order to secure and improve population 
coverage. The first designed vaccines on the market are expected 
to be an extension of the subunit vaccine approach extended with 
selected T-cell epitopes either inserted into the selected subunits or 
as individual peptides. Since these are still in the early development 
phase we will probably not see this kind of vaccines for human use 
on the market until 7–10 years from now at the earliest. However, 
for veterinary vaccines, the rational vaccine design approach might 
go much faster for the species in which detection protocols are 
established and the MHCs are known. We may even see vaccines 
on the market already at the end of the next 5-year period.
The development of computational methods in combination 
with general obtained biological knowledge will lead to the possi-
bility of highly personalized treatments. Such treatments might be 
seen in trials against otherwise untreatable serious diseases within 
a 5-year period and most certainly within the next 10 years.
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Key issues
• Full genome sequences of pathogens and somatic cells are available in ever-increasing amounts.
• Traditional T-cell epitope discovery methods are resource intensive despite development of intelligent assay methods and 
high-throughput systems.
• A number of T-cell epitope discovery methods are dependent on biological materials (e.g., patient blood samples), which are usually 
available in limiting amounts.
• High polymorphy of MHCs and length variation of reacting peptides further increase the number of experiments needed for traditional 
T-cell discovery.
• Accurate MHC binding prediction methods exists for all HLA class I and several mammal MHC class I proteins, for all HLA-DR proteins 
and several other MHC class II proteins.
• MHC class I binding predictions can be obtained even for peptides with an unusual epitope length.
• The use of MHC peptide binding predictions highly improve the success rates in epitope discovery and are easily integrated with, for 
example, sequence variation ana lysis.
• The combination of in silico, in vitro and ex vivo methods will, in the near future, be the optimal setup in epitope discovery.
• Predictions and mathematical models will not fully replace experimental methods.
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